Vaccination Coverage And Transmission Of Covid-19 In Palembang

Ahmad Ghiffari

Abstract


The COVID-19 pandemic has been going on for more than 3 years, and the vaccine is believed to eliminate the great danger of exposure to SARS-CoV-2. There is currently little understanding of the relationship between SARS-CoV-2 infection, and protection by vaccines. The descriptive research with an observational study is an ecology design approach examined the PCR confirmed COVID-19 cases and the coverage immunization. Total sampling data was collected by via secondary data, and were analyzed with temporal graphics. The first dose vaccination coverage was 54,63%, while the second dose was 46,53%. There was 30.320 confirmed cases during study, and the Ilir Barat 1 district with the highest number. Despite the under coverage of vaccines percentage, daily confirmed cases has decrease when the coverages reach 35%. Vaccination must be implemented to most of the society to achieve immunity protection against SARS-CoV-2 infection.

Full Text:

PDF

References


Umakanthan S, Sahu P, Ranade A V., Bukelo MM, Rao JS, Abrahao-Machado LF, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020;96(1142):753–8.

Vitiello A, Ferrara F, Troiano V, La Porta R. COVID-19 vaccines and decreased transmission of SARS-CoV-2. Inflammopharmacology. 2021;(0123456789):21–4.

Lazarus J V., Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225–8.

Speiser DE. COVID-19: Mechanisms of Vaccination and Immunity. Vaccines. 2020;8(404):1–19.

Dinas Kesehatan Kota Palembang. Update 8 Agustus 2021 Vaksinasi COVID-19 Kota Palembang. https://dinkes.palembang.go.id/?nmodul=berita&bhsnyo=id&bid=1343. 2021.

Kementerian Kesehatan RI. pandemi COVID-19. 2020.

Astuti NP, Nugroho EGZ, Lattu JC, Potempu IR, Swandana DA. Persepsi Masyarakat terhadap Penerimaan Vaksinasi Covid-19: Literature Review. J Keperawatan. 2021;13(3):569–80.

Harapan H, Wagner AL, Yufika A, Winardi W, Anwar S, Gan AK, et al. Willingness-to-pay for a COVID-19 vaccine and its associated determinants in Indonesia. Hum Vaccines Immunother [Internet]. 2020;00(00):1–7. Available from: https://doi.org/10.1080/21645515.2020.1819741

Minister of Health of Indonesia. Regulation of the Minister of Health of the Republic of Indonesia number 10 year 2021 on the Implementation of vaccination in order to combat pandemics. https://persi.or.id/wp-content/uploads/2021/02/pmk10-2021.pdf. 2021. p. 1–33.

Nugroho A. UGM Expert: Having an efficacy rate of 65.3 percent, Sinovac vaccine remains safe. Vol. January, https://www.ugm.ac.id/en/news/20611-ugm-expert-having-an-efficacy-rate-of-65-3-percent-sinovac-vaccine-remains-safe. 2021. p. 1–3.

Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al. Efficacy and safety of COVID-19 vaccines: A systematic review and meta-analysis of randomized clinical trials. Vaccines. 2021;9(467):1–21.

Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med [Internet]. 2021;(July):1–10. Available from: doi: 10.1056/NEJMoa2108891

Davies NG, Jarvis CI, van Zandvoort K, Clifford S, Sun FY, Funk S, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593(7858):270–4.

Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science (80- ). 2021;372(149):eabg3055.

Burki TK. News lifting of COVID-19 restrictions in the UK and the Delta variant. Lancet Respir [Internet]. 2021;2600(21):1. Available from: http://dx.doi.org/10.1016/S2213-2600(21)00328-3


Refbacks

  • There are currently no refbacks.


Sekretariat SENSORIK :

Ruang Jurnal Lantai 2, Gedung Cipto Mangunkusumo, Fakultas Kedokteran, UPN Veteran Jakarta, Indonesia.

Copyright © some right reserved Seminar Nasional Riset Kedokteran (SENSORIK).

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 International License.